Paper Details

  1. Home
  2. Paper Details

Use of Peripheral μ-Opioid Receptor Antagonists for Treating Opioid-Induced Constipation among US Medicare Beneficiaries from 2014 to 2018.

Author: DySydney M, GuptaArjun, JohnsonDavid H, PremnathNaveen, SedhomRamy, SubbiahIshwaria M, SumarsonoAndrew

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Opioid-induced constipation (OIC) is a common side effect of opioid use. While traditional laxatives are often effective, patients with persistent constipation may benefit from peripheral mu-opioid receptor antagonists (PAMORAs). This study examined the use and spending on three FDA-approved PAMORAs (methylnaltrexone, naloxegol, and naldemedine) from 2014 to 2018. Spending and use increased significantly during this period, with naloxegol surpassing methylnaltrexone in both categories. The study highlights the need for guidelines regarding the appropriate use of PAMORAs.
Paper Details　
Original Abstract of the Article :
<b><i>Background:</i></b> Opioid-induced constipation (OIC) remains the most common adverse event associated with opioid use. Treatment with more novel and costly agents (such as peripheral &#956;-opioid receptor antagonists [PAMORAs]) may be indicated in patients with laxative-refractory OIC. Thre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/jpm.2021.0021

データ提供：米国国立医学図書館（NLM）

Tackling Opioid-Induced Constipation: A Growing Trend of Peripheral μ-Opioid Receptor Antagonists

Opioid-induced constipation (OIC) is a common and often debilitating side effect of opioid use. This research investigates the trends in use and expenditures for peripheral μ-opioid receptor antagonists (PAMORAs) among Medicare beneficiaries from 2014 to 2018. The authors examine the patterns of PAMORA use across different specialties, exploring the potential for optimizing their use.

A Rising Tide: The Increasing Use of PAMORAs in Managing OIC

The study reveals a significant increase in both spending and use of PAMORAs for treating OIC among Medicare beneficiaries. This indicates a growing trend of reliance on these medications to manage OIC, suggesting a need for further research into their long-term efficacy and potential for overuse.

Navigating the Desert of OIC: Finding the Right Path to Relief

This research underscores the importance of promoting appropriate and judicious use of PAMORAs. It emphasizes the need for ongoing research to ensure their effectiveness and safety in managing OIC, minimizing potential risks associated with overuse and promoting the optimal use of these medications.

Dr. Camel's Conclusion

The desert of OIC can be a difficult place to navigate. PAMORAs offer a potential oasis, but it's crucial to use them wisely. This research sheds light on the increasing use of these drugs, highlighting the need for careful consideration and responsible use to ensure the well-being of patients.

Date :
  1. Date Completed 2021-08-10
  2. Date Revised 2021-08-10
Further Info :

Pubmed ID

33872062

DOI: Digital Object Identifier

10.1089/jpm.2021.0021

Related Literature

Article Analysis
・Effects of naloxegol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.